5 research outputs found
Identifying Ancient Conserved Non-Coding DNA Elements
DNA is the genetic material at the root of all life, and serves as the \u27instructions\u27 for biomolecular mechanisms to shape the bodies and synthesize the chemicals that make up an organism. DNA mutations and the forces of natural selection drive the evolution that has resulted in the tremendous diversity of life on earth today. However, despite life\u27s staggering diversity, there still exist many sequences of DNA that share remarkable similarity between organisms, even between species as different as humans and bacteria. This is called conservation. Most conserved DNA encodes genes that produce proteins or RNA that are crucial to the survival of an organism. Here, we seek to understand DNA that remains highly conserved, perhaps over hundreds of millions of years, yet does not encode genes at all. The conservation of such DNA indicates some role that, while vital to species survival, remains to be understood. We employed open source computational tools and developed custom genomics analysis software to investigate these highly conserved non-coding sequences of DNA. Regions of the human genome known to encode proteins and RNA were masked, and the remaining genome was aligned with that of fugu fish (a species with which homo sapiens shares a common ancestor that lived over 400 million years ago) in order to shared reveal noncoding sequences. The collected sequences were then cross-correlated with numerous databases detailing genomic features, with the aim of clustering conserved elements tied to similar features and inferring underlying function
Integration of protein phosphorylation, acetylation, and methylation data sets to outline lung cancer signaling networks
Integrated multiomics network analysis reveals signaling profiles in lung cancer.</jats:p
A community effort in SARS-CoV-2 drug discovery.
peer reviewedThe COVID-19 pandemic continues to pose a substantial threat to human lives and is likely to do so for years to come. Despite the availability of vaccines, searching for efficient small-molecule drugs that are widely available, including in low- and middle-income countries, is an ongoing challenge. In this work, we report the results of an open science community effort, the "Billion molecules against Covid-19 challenge", to identify small-molecule inhibitors against SARS-CoV-2 or relevant human receptors. Participating teams used a wide variety of computational methods to screen a minimum of 1 billion virtual molecules against 6 protein targets. Overall, 31 teams participated, and they suggested a total of 639,024 molecules, which were subsequently ranked to find 'consensus compounds'. The organizing team coordinated with various contract research organizations (CROs) and collaborating institutions to synthesize and test 878 compounds for biological activity against proteases (Nsp5, Nsp3, TMPRSS2), nucleocapsid N, RdRP (only the Nsp12 domain), and (alpha) spike protein S. Overall, 27 compounds with weak inhibition/binding were experimentally identified by binding-, cleavage-, and/or viral suppression assays and are presented here. Open science approaches such as the one presented here contribute to the knowledge base of future drug discovery efforts in finding better SARS-CoV-2 treatments.R-AGR-3826 - COVID19-14715687-CovScreen (01/06/2020 - 31/01/2021) - GLAAB Enric
Drugsniffer: An Open Source Workflow for Virtually Screening Billions of Molecules for Binding Affinity to Protein Targets
The SARS-CoV2 pandemic has highlighted the importance of efficient and effective methods for identification of therapeutic drugs, and in particular has laid bare the need for methods that allow exploration of the full diversity of synthesizable small molecules. While classical high-throughput screening methods may consider up to millions of molecules, virtual screening methods hold the promise of enabling appraisal of billions of candidate molecules, thus expanding the search space while concurrently reducing costs and speeding discovery. Here, we describe a new screening pipeline, called drugsniffer, that is capable of rapidly exploring drug candidates from a library of billions of molecules, and is designed to support distributed computation on cluster and cloud resources. As an example of performance, our pipeline required âŒ40,000 total compute hours to screen for potential drugs targeting three SARS-CoV2 proteins among a library of âŒ3.7 billion candidate molecules
A community effort to discover small molecule SARS-CoV-2 inhibitors
The COVID-19 pandemic continues to pose a substantial threat to human lives and is likely to do so for years to come. Despite the availability of vaccines, searching for efficient small-molecule drugs that are widely available, including in low- and middle-income countries, is an ongoing challenge. In this work, we report the results of a community effort, the âBillion molecules against Covid-19 challengeâ, to identify small-molecule inhibitors against SARS-CoV-2 or relevant human receptors. Participating teams used a wide variety of computational methods to screen a minimum of 1 billion virtual molecules against 6 protein targets. Overall, 31 teams participated, and they suggested a total of 639,024 potentially active molecules, which were subsequently ranked to find âconsensus compoundsâ. The organizing team coordinated with various contract research organizations (CROs) and collaborating institutions to synthesize and test 878 compounds for activity against proteases (Nsp5, Nsp3, TMPRSS2), nucleocapsid N, RdRP (Nsp12 domain), and (alpha) spike protein S. Overall, 27 potential inhibitors were experimentally confirmed by binding-, cleavage-, and/or viral suppression assays and are presented here. All results are freely available and can be taken further downstream without IP restrictions. Overall, we show the effectiveness of computational techniques, community efforts, and communication across research fields (i.e., protein expression and crystallography, in silico modeling, synthesis and biological assays) to accelerate the early phases of drug discovery